Funds and ETFs Biogen Inc.

Equities

BIIB

US09062X1037

Pharmaceuticals

Market Closed - Nasdaq 21:00:00 10/05/2024 BST 5-day change 1st Jan Change
221.5 USD -0.56% Intraday chart for Biogen Inc. +1.83% -14.40%

ETFs positioned on Biogen Inc.

Name Weight AuM 1st Jan change Investor Rating
0.21% 0 M€ +1.41% -
0.21% 0 M€ +5.63% -
0.20% 219 M€ +17.17% -
0.20% 1,448 M€ -.--% -
0.20% 0 M€ +9.42%
0.20% 330 M€ -.--%
0.20% 2 M€ +14.69% -
0.18% 0 M€ +18.09% -
0.18% 0 M€ +4.60% -
0.18% 0 M€ +8.70%
0.18% 276 M€ +11.40% -
0.18% 1,174 M€ +23.54%
0.18% 655 M€ -.--% -
0.18% 273 M€ -.--%
0.17% 36 M€ +22.19%
0.17% 0 M€ +8.06%
0.16% 0 M€ +18.44% -
0.15% 0 M€ +12.85%
0.14% 1,848 M€ +18.39%
0.14% 559 M€ +14.30%
0.13% 1 M€ +0.04%
0.12% 6 M€ +17.98% -
0.12% 0 M€ +6.97% -
0.12% 0 M€ +3.90% -
0.12% 0 M€ +4.20% -
0.12% 205 M€ -.--%
0.11% 0 M€ +19.88% -
0.10% 0 M€ -.--% -
0.10% 0 M€ +9.15% -
0.10% 0 M€ +11.72%
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (17,2%) ; - other (9,1%): primarily revenues from partnership agreements.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
221.5 USD
Average target price
285.9 USD
Spread / Average Target
+29.08%
Consensus
  1. Stock Market
  2. Equities
  3. BIIB Stock
  4. Funds and ETFs Biogen Inc.